Scott J. Rodig

ORCID: 0000-0003-1761-9769 · 1 paper in corpus
article 2016
·doi:10.1200/jco.2016.34.15_suppl.5514

5514 Background: Studies of immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies) in ovarian cancer have demonstrated isolated responses in tumors with clear cell histology. In order to assess the immunogenicity of clear cell ovar…